These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 38672120)

  • 21. Comparison of the tumor immune microenvironment and checkpoint blockade biomarkers between stage III and IV non-small cell lung cancer.
    Gao Y; Stein MM; Kase M; Cummings AL; Bharanikumar R; Lau D; Garon EB; Patel SP
    Cancer Immunol Immunother; 2023 Feb; 72(2):339-350. PubMed ID: 35881197
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comprehensive Testing of Chemotherapy and Immune Checkpoint Blockade in Preclinical Cancer Models Identifies Additive Combinations.
    Principe N; Aston WJ; Hope DE; Tilsed CM; Fisher SA; Boon L; Dick IM; Chin WL; McDonnell AM; Nowak AK; Lake RA; Chee J; Lesterhuis WJ
    Front Immunol; 2022; 13():872295. PubMed ID: 35634282
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.
    Chan TA; Yarchoan M; Jaffee E; Swanton C; Quezada SA; Stenzinger A; Peters S
    Ann Oncol; 2019 Jan; 30(1):44-56. PubMed ID: 30395155
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intralesional administration of VAX014 facilitates in situ immunization and potentiates immune checkpoint blockade in immunologically cold tumors.
    Reil KA; Tsuji S; Molina E; Nelson KL; McGuire KL; Giacalone MJ
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37290924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Repurposing Azacitidine and Carboplatin to Prime Immune Checkpoint Blockade-resistant Melanoma for Anti-PD-L1 Rechallenge.
    van der Westhuizen A; Lyle M; Graves MC; Zhu X; Wong JWH; Cornall K; Ren S; Pugliese L; Levy R; Majid A; Vilain RE; Bowden NA
    Cancer Res Commun; 2022 Aug; 2(8):814-826. PubMed ID: 36923309
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor-Associated Antigen Burden Correlates with Immune Checkpoint Blockade Benefit in Tumors with Low Levels of T-cell Exhaustion.
    Wang Y; Hu M; Finn OJ; Wang XS
    Cancer Immunol Res; 2024 Nov; 12(11):1589-1602. PubMed ID: 39137006
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19-IL2 cures poorly immunogenic tumors when combined with radiotherapy.
    Olivo Pimentel V; Marcus D; van der Wiel AM; Lieuwes NG; Biemans R; Lieverse RI; Neri D; Theys J; Yaromina A; Dubois LJ; Lambin P
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33688020
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
    Han X; Li H; Zhou D; Chen Z; Gu Z
    Acc Chem Res; 2020 Nov; 53(11):2521-2533. PubMed ID: 33073988
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tubeimoside-1 induces TFEB-dependent lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting mTOR.
    Liu X; Yin M; Dong J; Mao G; Min W; Kuang Z; Yang P; Liu L; Zhang N; Deng H
    Acta Pharm Sin B; 2021 Oct; 11(10):3134-3149. PubMed ID: 34745852
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD4
    Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death.
    Moon Y; Shim MK; Choi J; Yang S; Kim J; Yun WS; Cho H; Park JY; Kim Y; Seong JK; Kim K
    Theranostics; 2022; 12(5):1999-2014. PubMed ID: 35265195
    [No Abstract]   [Full Text] [Related]  

  • 32. Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma.
    Placke JM; Soun C; Bottek J; Herbst R; Terheyden P; Utikal J; Pföhler C; Ulrich J; Kreuter A; Pfeiffer C; Mohr P; Gutzmer R; Meier F; Dippel E; Weichenthal M; Zimmer L; Livingstone E; Becker JC; Lodde G; Sucker A; Griewank K; Horn S; Hadaschik E; Roesch A; Schadendorf D; Engel DR; Ugurel S
    Front Oncol; 2021; 11():741993. PubMed ID: 34621681
    [TBL] [Abstract][Full Text] [Related]  

  • 33. S100A9
    Tu X; Chen L; Zheng Y; Mu C; Zhang Z; Wang F; Ren Y; Duan Y; Zhang H; Tong Z; Liu L; Sun X; Zhao P; Wang L; Feng X; Fang W; Liu X
    J Exp Clin Cancer Res; 2024 Mar; 43(1):72. PubMed ID: 38454445
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
    Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunohistochemical scoring of LAG-3 in conjunction with CD8 in the tumor microenvironment predicts response to immunotherapy in hepatocellular carcinoma.
    Cheung CCL; Seah YHJ; Fang J; Orpilla NHC; Lau MC; Lim CJ; Lim X; Lee JNLW; Lim JCT; Lim S; Cheng Q; Toh HC; Choo SP; Lee SY; Lee JJX; Liu J; Lim TKH; Tai D; Yeong J
    Front Immunol; 2023; 14():1150985. PubMed ID: 37342338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice.
    Pieper AA; Rakhmilevich AL; Spiegelman DV; Patel RB; Birstler J; Jin WJ; Carlson PM; Charych DH; Hank JA; Erbe AK; Overwijk WW; Morris ZS; Sondel PM
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34172518
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes.
    Dammeijer F; van Gulijk M; Mulder EE; Lukkes M; Klaase L; van den Bosch T; van Nimwegen M; Lau SP; Latupeirissa K; Schetters S; van Kooyk Y; Boon L; Moyaart A; Mueller YM; Katsikis PD; Eggermont AM; Vroman H; Stadhouders R; Hendriks RW; Thüsen JV; Grünhagen DJ; Verhoef C; van Hall T; Aerts JG
    Cancer Cell; 2020 Nov; 38(5):685-700.e8. PubMed ID: 33007259
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer.
    Wan C; Keany MP; Dong H; Al-Alem LF; Pandya UM; Lazo S; Boehnke K; Lynch KN; Xu R; Zarrella DT; Gu S; Cejas P; Lim K; Long HW; Elias KM; Horowitz NS; Feltmate CM; Muto MG; Worley MJ; Berkowitz RS; Matulonis UA; Nucci MR; Crum CP; Rueda BR; Brown M; Liu XS; Hill SJ
    Cancer Res; 2021 Jan; 81(1):158-173. PubMed ID: 33158814
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer.
    Lal JC; Townsend MG; Mehta AK; Oliwa M; Miller E; Sotayo A; Cheney E; Mittendorf EA; Letai A; Guerriero JL
    Breast Cancer Res; 2021 Aug; 23(1):83. PubMed ID: 34353349
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of primary and metastatic site-related PD-L1 expression in predicting ORR in patients with advanced NSCLC who received ICB-based therapy.
    Zhou D; Wang Y; Ning W; Chen C
    Thorac Cancer; 2024 Feb; 15(5):379-385. PubMed ID: 38155421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.